X0306 4 2020-02-17 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2020-02-17 4 F 0 2496 241.50 D 44839 D Common Stock 2020-02-18 4 S 0 760 242.08 D 44079 D Common Stock 2020-02-18 4 S 0 1011 242.91 D 43068 D Common Stock 2020-02-18 4 S 0 400 243.76 D 42668 D Common Stock 2020-02-18 4 S 0 580 245.04 D 42088 D Common Stock 2020-02-18 4 S 0 377 245.76 D 41711 D Common Stock 140 I 401(k) Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $242.08 (range $241.41 to $242.38). Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $242.91 (range $242.43 to $243.42). Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.45 to $244.43). Open market sales reported on this line occurred at a weighted average price of $245.04 (range $244.52 to $245.44). Open market sales reported on this line occurred at a weighted average price of $245.76 (range $245.54 to $245.90). /s/ Omar White, Attorney-in-Fact 2020-02-19